In a phase II study of adavosertib in combination with carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line platinum-based therapy, patients were re-exposed to carboplatin and thus served as their own control [14]. The gene discussed is TP53; the disease is ovarian cancer.